Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Rehabilitation for balance and gait issues in multiple sclerosis patients using technology

Official title: Technological Balance and Gait Rehabilitation in Patients With Multiple Sclerosis: Effects on Functional, Motor and Cognitive Outcomes (ROAR-MS).

Run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05983809 · Data updated 2026-11-12

This study is testing if a new robotic rehabilitation program can help people with multiple sclerosis improve their balance and walking over a year.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment24 (estimated)
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Academic / other
Locations1 site (Roma, RM)
StatusRecruiting
StartedSeptember 15, 2023
Main results expectedMarch 31, 2024
Study endsMay 2026
Registry record updatedJuly 14, 2025
Trial IDNCT05983809 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 to 65 with a definitive diagnosis of multiple sclerosis and moderate balance issues.

Probably not a fit

Patients with severe cognitive impairment, significant visual impairment, or unrelated vestibular disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial focuses on patients with multiple sclerosis (MS) who experience balance and cognitive impairments. It involves a randomized approach where participants are divided into two groups: one receiving technological rehabilitation using the Hunova robotic platform, while the other group undergoes observation before receiving the same treatment. The study aims to evaluate the effectiveness of this innovative rehabilitation method over a 12-month period. Participants will be assessed for their ability to stand and follow instructions, ensuring they meet specific inclusion criteria.

Why it matters

Potential benefit: If successful, this study could significantly improve balance and mobility in patients with multiple sclerosis, enhancing their quality of life.

How similar studies have gone: Previous studies have shown promise in using technology for rehabilitation in similar patient populations, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Definitive diagnosis of multiple sclerosis according to McDonald criteria;
* Age between 18 and 65 years;
* Pyramidal or cerebellar system with a score ≥ 2 on the EDSS;
* EDSS between 2 and 3;
* Ability to stand without support for 60 seconds;
* Stability of disease-modifying treatment and absence of clinical relapse of the disease for at least 1 year;
* Cognitive ability to execute simple orders and understand the physiotherapist's instructions \[assessed by Token Test (score ≥ 26.5)\];
* Ability to understand and sign informed consent.

Exclusion Criteria:

* Significant visual impairment, defined by a visual system score ≥ 2 on the EDSS;
* Presence of vestibular disorders unrelated to MS;
* Presence of psychiatric disorders or severe cognitive impairment, i.e. a Mini Mental State Examination (MMSE) score \< 24 (15);
* Presence of cardiovascular and respiratory disorders;
* Inability to provide informed consent.

Where it's running

  • Fondazione Policlinico Universitario A. Gemelli IRCCS
    Roma, Rm, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.